Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:30 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 13,266 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Adult Disease Clear all

Conditions: MASLD, Fatty Liver
Interventions: Peanut consumption; Other
Lead sponsor: Henry Ford Health System; Other
Eligibility: 30 Years to 70 Years
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Obstructive Hypertrophic Cardiomyopathy (oHCM)
Interventions: Aficamten (5 mg, 10 mg, 15 mg, and 20 mg), Placebo to match aficamten; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 48
States / cities: Anchorage, Alaska • La Jolla, California • Los Angeles, California + 39 more

Conditions: Type 1 Diabetes
Interventions: 670G and 770G Insulin Pump, Subject's Current Diabetes Therapy; Device
Lead sponsor: Medtronic MiniMed, Inc.; Industry
Eligibility: 2 Years to 80 Years
Enrollment: 959 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 25
States / cities: La Jolla, California • Palo Alto, California • Sacramento, California + 21 more

Conditions: Sickle Cell Disease
Interventions: Morphine, Methadone; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 7 Years to 40 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Leukemia, Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: 7-hydroxystaurosporine; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Autism Spectrum Disorder, Autism
Interventions: Virtual Reality Intervention, Video Modeling Intervention, No intervention; Behavioral
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 12 Years to 60 Years
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Mild Cognitive Impairment, Healthy Aging
Interventions: RFB, VSOP, IR; Behavioral
Lead sponsor: University of Rochester; Other
Eligibility: 60 Years to 89 Years
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Becker Muscular Dystrophy
Interventions: Sevasemten; Drug
Lead sponsor: Edgewise Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Lymphoid Leukemia, Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia, Relapsed Acute Lymphoblastic Leukemia
Interventions: CPX-351; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Atherosclerosis
Interventions: Rosuvastatin 10 mg, Darapladib 160 mg; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 20 Years to 64 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Glendale, California

Conditions: Rectovaginal Fistula, Crohn Disease, Crohn Disease of Vulva, Rectolabial; Fistula
Interventions: Mesenchymal Stem Cells, Placebo; Drug · Other
Lead sponsor: Anthony Lembo; Other
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Dermatomyositis
Interventions: human immunoglobulin G, Placebo; Drug
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years and older
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 15
States / cities: Glendale, Arizona • Phoenix, Arizona • Los Angeles, California + 12 more

Conditions: Von Willebrand Disease, Blood Coagulation Disorders, Blood Platelet Disorders, Hematologic Disease
Interventions: Blood coagulation Factor VIII and vWF, human; Drug
Lead sponsor: CSL Behring; Industry
Eligibility: Not listed
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: 3'-deoxy-3'-[18F]fluorothymidine; Device
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 18 Years to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2027
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions: busulfan, melphalan, methotrexate, tacrolimus, allogeneic bone marrow transplantation; Drug · Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2007
U.S. locations: 1
States / cities: New York, New York

Conditions: Overweight, Obesity
Interventions: Deaf Weight Wise program; Behavioral
Lead sponsor: University of Rochester; Other
Eligibility: 40 Years to 70 Years
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Hypercholesterolemia
Interventions: Enlicitide Decanoate; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 52
States / cities: Daphne, Alabama • Foley, Alabama • Phoenix, Arizona + 48 more

Conditions: Adult Solid Tumor, Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Adult Central Nervous System Germ Cell Tumor, Adult Teratoma, Benign Teratoma, Estrogen Receptor-negative Breast Cancer, Estrogen Receptor-positive Breast Cancer, Familial Testicular Germ Cell Tumor, HER2-negative Breast Cancer, HER2-positive Breast Cancer, Male Breast Cancer, Ovarian Immature Teratoma, Ovarian Mature Teratoma, Ovarian Monodermal and Highly Specialized Teratoma, Progesterone Receptor-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer, Recurrent Colon Cancer, Recurrent Extragonadal Germ Cell Tumor, Recurrent Extragonadal Non-seminomatous Germ Cell Tumor, Recurrent Extragonadal Seminoma, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Melanoma, Recurrent Ovarian Germ Cell Tumor, Recurrent Rectal Cancer, Stage III Extragonadal Non-seminomatous Germ Cell Tumor, Stage III Extragonadal Seminoma, Stage III Malignant Testicular Germ Cell Tumor, Stage III Ovarian Germ Cell Tumor, Stage IV Breast Cancer, Stage IV Colon Cancer, Stage IV Extragonadal Non-seminomatous Germ Cell Tumor, Stage IV Extragonadal Seminoma, Stage IV Melanoma, Stage IV Ovarian Germ Cell Tumor, Stage IV Rectal Cancer, Testicular Immature Teratoma, Testicular Mature Teratoma
Interventions: PD-0332991; Drug
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Lassa Fever, Lassa Virus Infection
Interventions: rVSV∆G-LASV-GPC, Placebo/Diluent; Drug · Other
Lead sponsor: International AIDS Vaccine Initiative; Network
Eligibility: 18 Years to 51 Years
Enrollment: 114 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • Honolulu, Hawaii • Brookline, Massachusetts

Conditions: Fall, Fall Injury, Peripheral Artery Disease, Peripheral Arterial Disease
Interventions: Adapted Otago Exercise Program (OEP); Behavioral
Lead sponsor: University of Minnesota; Other
Eligibility: 60 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Older Adults, Anxiety, Depression, Cardiac Surgery, Orthopedic Surgery, Major Surgical Resection of a Thoracic Malignancy, Major Surgical Resection of an Abdominal Malignancy
Interventions: Behavioral Activation, Medication Optimization; Behavioral · Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 60 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Duchenne Muscular Dystrophy
Interventions: delandistrogene moxeparvovec; Genetic
Lead sponsor: Sarepta Therapeutics, Inc.; Industry
Eligibility: 2 Years and older · Male only
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 12
States / cities: Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 9 more

Conditions: Depression, Major Depressive Episode, Bipolar Disorder
Interventions: MagVenture MagPro MST, RUL ECT; Device · Biological
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 55 Years to 90 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Myelogenous Leukemia, Acute, Myelodysplastic Syndromes
Interventions: MGCD0103; Drug
Lead sponsor: Mirati Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 6
States / cities: Kansas City, Missouri • Rochester, New York • Canton, Ohio + 3 more

Search by objective public record fields.

Effects of Peanut Consumption on Adults With Metabolic Associated Fatty Liver Disease

Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM

Multi-center Trial in Adult and Pediatric Patients With Type 1 Diabetes Using Hybrid Closed Loop System and Control at Home

Methadone in Pediatric and Adult Sickle Cell Patients

UCN-01 in Treating Patients With Advanced Cancer

VR Intervention to Improve Police Safety

Breathing, Relaxation, Attention Training, & Health in Older Adults (BREATHE)

A Study of EDG-5506 in Adult Males With Becker Muscular Dystrophy

Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic Leukemia

To Estimate the Potential Effects of Repeat Doses of Darapladib on the Pharmacokinetics (PK) of Rosuvastatin as Well as Evaluating Safety and Tolerability in Healthy Volunteers

Mesenchymal Stem Cells for the Treatment of Rectovaginal Fistulas in Participants With Crohn's Disease

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM)

Study of Safety and Efficacy of Antihemophilic Factor/Von Willebrand Factor Complex in Surgical Subjects With Von Willebrand Disease (vWD)

3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer

Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Advanced Hematologic Cancer

Study of a Healthy Lifestyle Intervention for Deaf Adults Who Are Overweight or Obese

Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension

Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer

A Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-LASV-GPC Vaccine in Adults in Good General Heath

Integrating Fall Prevention Balance Exercises Into a Program for Older Adults With Peripheral Artery Disease (PAD): A Mixed Methods Feasibility Study

Behavioral Activation and Medication Optimization for Perioperative Mental Health Feasibility Study

A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD) - Non-Ambulatory Cohort

Study Comparing Magnetic Seizure Therapy (MST) to Electroconvulsive Therapy (ECT) for Depression in Older Adults

MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory Disease